MetaCap

Bio-Rad Laboratories (BIO) vs Bruker (BRKR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bruker (BRKR) has outperformed Bio-Rad Laboratories (BIO) over the past year, gaining 19.4% versus a gain of 13.3%. Over five years, BRKR leads with a -32.2% price change compared with -52.2% for BIO. Bio-Rad Laboratories is the larger company by market cap ($9.65 billion vs $8.62 billion), about 1.1 times the size, while Bruker is growing revenue faster (+2.1% vs +0.7%).

On valuation, Bruker trades at a lower forward P/E (23.3x vs 36.2x for Bio-Rad Laboratories). Bruker pays a dividend yielding 0.09%, while Bio-Rad Laboratories does not currently pay one. Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus -0.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIO+13.32%BRKR+19.44%
+44%+5%-34%
Nov 21, 20251 yearNov 20, 2026
BIO-53.79%BRKR-32.64%
+16%-30%-76%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIO versus BRKR key metrics
MetricBIOBRKR
Share price$358.90$56.46
Market cap$9.65B$8.62B
1-day change-2.34%-9.08%
YTD return+18.45%+19.85%
1-year return+13.32%+19.44%
5-year return-52.16%-32.16%
P/E ratio (TTM)9.54—
Forward P/E36.2323.25
EPS (TTM)$37.64$-1.10
Dividend yield0.00%0.09%
Annual dividend$0.00$0.05
Revenue (latest FY)$2.58B$3.44B
Revenue growth (YoY)+0.65%+2.08%
Net income (latest FY)$759.90M$-8.60M
Gross margin51.87%45.91%
Operating margin1.83%1.98%
Net margin29.42%-0.25%
52-week high$396.23$68.98
52-week low$236.73$32.37
Distance from 52-week high-9.42%-18.15%
Analyst consensusholdbuy
Avg. price target upside-0.62%+20.44%
Average volume257.70K2.32M
Shares outstanding21.83M152.72M
Employees7,45011,085
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -0.3 cents for Bruker.

About Bio-Rad Laboratories

BIO stock →

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.

Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees

About Bruker

BRKR stock →

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Industrials · Biotechnology: Laboratory Analytical Instruments · 11,085 employees

BIO vs BRKR FAQ

Which is bigger, Bio-Rad Laboratories or Bruker?

Bio-Rad Laboratories (BIO) is larger, with a market capitalization of $9.65B compared with $8.62B for Bruker (BRKR).

Which stock has performed better over the past year, BIO or BRKR?

BRKR returned +19.44% over the past 12 months, compared with +13.32% for BIO (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Bio-Rad Laboratories or Bruker?

Bruker pays a dividend yielding 0.09%, while Bio-Rad Laboratories does not currently pay a regular dividend.

Are Bio-Rad Laboratories and Bruker in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons